Experimental study of a mixed vaccine against peste des petits ruminants and capripox infection in goats in Northern Cameroon
A mixed vaccine against peste des petits ruminants (PPR) and capripox infection was investigated in Northern Cameroon. The vaccine strains were the attenuated PPRV/75/1 strain for PPR and the RM 65 strain for Capripox disease. 25 goats were vaccinated with different doses of the vaccine to study the seroconversion. In another experiment, 20 goats were vaccinated and then challenged with wild virulent strains of PPR and goat pox. The measure of the seroconversion as well as the challenge experiments demonstrated that PPR valence was effective at least till the 10exp0.8 tissue culture infective dose 50. However the capripox valence appeared not to be protective despite the apparition of neutralising antibodies. The economical benefits of using a low dose of vaccine against PPR are discussed. Further studies with new vaccinal strains of capripox viruses are recommended before investigating clinical field trials.
| Main Authors: | , , |
|---|---|
| Format: | article biblioteca |
| Language: | eng |
| Subjects: | L73 - Maladies des animaux, caprin, capripoxvirus, peste des petits ruminants, vaccin associé, expérimentation, http://aims.fao.org/aos/agrovoc/c_3324, http://aims.fao.org/aos/agrovoc/c_1284, http://aims.fao.org/aos/agrovoc/c_16789, http://aims.fao.org/aos/agrovoc/c_16405, http://aims.fao.org/aos/agrovoc/c_2758, http://aims.fao.org/aos/agrovoc/c_1229, |
| Online Access: | http://agritrop.cirad.fr/389901/ http://agritrop.cirad.fr/389901/1/389901.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | A mixed vaccine against peste des petits ruminants (PPR) and capripox infection was investigated in Northern Cameroon. The vaccine strains were the attenuated PPRV/75/1 strain for PPR and the RM 65 strain for Capripox disease. 25 goats were vaccinated with different doses of the vaccine to study the seroconversion. In another experiment, 20 goats were vaccinated and then challenged with wild virulent strains of PPR and goat pox. The measure of the seroconversion as well as the challenge experiments demonstrated that PPR valence was effective at least till the 10exp0.8 tissue culture infective dose 50. However the capripox valence appeared not to be protective despite the apparition of neutralising antibodies. The economical benefits of using a low dose of vaccine against PPR are discussed. Further studies with new vaccinal strains of capripox viruses are recommended before investigating clinical field trials. |
|---|